Search the site
Court Proceedings
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding apixaban.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding apixaban.
Application under the Patented Medicines (Notice of Compliance) Regulations regarding silodosin.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding linagliptin.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding linagliptin.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding linagliptin.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding linagliptin.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding linagliptin.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding linagliptin.
Application under s.18.1 of the Patented Medicines (Notice of Compliance) Regulations regarding lenalidomide.
Trademark opposition before the Trade‑marks Opposition Board (2025 TMOB 241).
Proceeding for patent impeachment relating to pembrolizumab.
Application for a declaration of non‑infringement regarding pembrolizumab.
Application for a declaration of non‑infringement regarding pembrolizumab.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding empagliflozin.
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,652,442 and 2,771,403 (lenvatinib).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,632,375 (diclofenac).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,932,603 (diclofenac).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,606,282, 2,967,453, and 3,003,988 (dolutegravir-abacavir-lamivudine).
Counsel to defendants in patent infringement action relating to use of imazamox herbicides regarding Patent No. 2,447,445.
Counsel to respondent trademark owner in expungement proceedings regarding trademark TMA822855. Successfully applied for dismissal of proceeding due to undue and inexcusable delay (2024 FC 579).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,606,282 (dolutegravir).
Counsel to defendants in trademark infringement and passing off action relating to agricultural products regarding trademark TMA483211. Settled on favourable terms.
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,671,357 (canagliflozin).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,534,024 (canagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,655,212 and 2,705,163 (vortioxetine).
Counsel to defendants in patent infringement action relating to laminate flooring regarding Patent Nos. 2,522,321, 2,226,286, 2,410,206, and 2,475,076.
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,832,157 (brexpiprazole).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,602,247 (brexpiprazole).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,851,588 (brexpiprazole).
Counsel to the opponent in trademark opposition relating to industrial equipment. Successfully opposed registration of mark (2023 TMOB 64).
Counsel to trademark owner in expungement proceedings. Successfully maintained marks (2023 TMOB 43; 2023 TMOB 44; 2023 TMOB 45).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,752,437 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,936,852, 2,485,143, 2,544,621 and 2,781,799 (riociguat).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,696,558 and 2,752,435 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,649,922 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,732,803 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,472,399, 2,590,511 and 2,703,598 (sacubitril/valsartan).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,782,179 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,696,558 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,738,367 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,557,801, 2,606,650, 2,751,833 and 2,813,661 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,496,249 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,589,765, 2,589,921, 2,701,778, 2,741,312 and 2,873,044 (carfilzomib).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,845,553 and 2,990,210 (tenofovir alafenamide/emtricitabine).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,845,553 (tenofovir alafenamide).
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,682,598 with respect to products containing sapropterin.
Actions under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,450,740, No. 2,529,400 and No. 2,536,251 as well as patent infringement actions relating to Patent No. 2,518,435 with respect to products containing sitagliptin and products containing both sitagliptin and metformin.
Action for copyright infringement. Acting as counsel on motions relating to the Statement of Claim and appeals therefrom.
Counsel to the defendants in patent infringement action relating to control system for lift axles on vehicles regarding Patent No. 2,756,470. Settled shortly before trial on favourable terms.
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent Nos. 2,440,472, 2,521,885, and 2,803,922 (doxycycline).
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent Nos. 2,621,273 and 2,659,770 (macitentan).
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,794,060 (pomalidomide).
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,752,550 (pomalidomide).
Application for leave to appeal to the Supreme Court of Canada in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,402,894 (saxagliptin).
Counsel to defendants in copyright infringement proceeding. Proceeding dismissed (2019 FC 1199).
Interlocutory appeal in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,819,967 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,358 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,014 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,631,646 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,937,365 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,667,654 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,620,380 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,709,997 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,762,013 and 2,620,380 (pirfenidone).
Patent infringement regarding Patent No. 2,743,326 (daptomycin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,344,318 and 2,743,326 (daptomycin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,461,202 (apixaban).
Appeal of a trademark expungement case regarding Registration Nos. TMDA22577 and UCA44562 (HORLICKS).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,791,171 (apixaban).
Counsel to appellant in appeal of judgment of patent infringement. Successful on appeal and matter remitted to trial judge for re-determination in accordance with appeal reasons (2018 FCA 140). Matter subsequently settled.
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,823,159, 2,634,310 and 2,547,113 (rivaroxaban).
CIRA domain name dispute relating to the domain name STRIPMEISTER.CA.
Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab).
Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab).
Appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab).
Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab).
Statutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab).
Action under the Trademarks Act and the Competition Act regarding Registration Nos. TMA580,557 (ENERGIZER MAX), TMA157,162 (ENERGIZER) and TMA740,338 (ENERGIZER).
Motion/Application under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,823,159, 2,634,310 and 2,547,113 (rivaroxaban).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,507,002 and 2,496,780 (silodosin).
Patent impeachment case regarding Patent No. 2,596,133 (trastuzumab).
Patent infringement case regarding Patent No. 2,787,952 (bevacizumab) with counterclaim for infringement under the new Patented Medicines (Notice of Compliance) Regulations.
Patent impeachment case regarding Patent No. 2,376,596 (trastuzumab).
Patent impeachment case regarding Patent No. 2,329,829 (trastuzumab).
Patent impeachment case regarding Patent No. 2,540,547 (trastuzumab).
